Our Services
Medical Information
Helpful Resources
Published on: 5/6/2026
Weight loss plateaus are commonly caused by metabolic adaptation and hormonal shifts that stall progress despite consistent diet and exercise. Emerging research highlights GIP peptides as a key driver of improved insulin response, enhanced fat metabolism, and amplified results when combined with GLP-1 agonists like the FDA-approved tirzepatide.
Before starting dual agonist therapy, it's important to understand GIP peptide mechanisms, approved treatment options, lifestyle strategies, and safety considerations outlined below.
If you're struggling with unexplained weight changes, fatigue, or metabolic symptoms, don't guess what's driving your plateau. Take a free, instant, online symptom check to better understand what's going on in your body and get clear, personalized guidance on your next steps—before considering advanced treatments like GIP or GLP-1 therapies.
Reviewed for medical accuracy: 07/09/2026
Hitting a weight loss plateau—or "stall"—can be frustrating. You've been diligent with your diet and exercise, yet the scale refuses to budge. Recent advances in metabolic science point to certain hormones as key drivers in overcoming these stalls. One such hormone is GIP (glucose-dependent insulinotropic polypeptide). Below, we'll explore why GIP peptides are crucial, what treatments are medically approved, and practical next steps.
A weight stall occurs when:
Why it happens:
Hormones are chemical messengers that regulate appetite, metabolism, and fat storage. Two major incretin hormones are:
Most weight-loss medications target GLP-1, but GIP is gaining attention for its complementary effects.
GIP peptides are short chains of amino acids that mimic the action of natural GIP. Key points:
Research shows that using GIP peptides, especially in combination with GLP-1 analogs, can lead to greater reductions in body weight and improved blood sugar control than targeting GLP-1 alone.
Enhanced Insulin Response
Dual-Agonist Synergy
Improved Fat Metabolism
Better Tolerance
Currently, the most advanced treatments combining GIP and GLP-1 activity include:
Tirzepatide (Mounjaro®)
• Originally approved for type 2 diabetes, now also indicated for chronic weight management in adults.
• Administered via weekly injection.
• Clinical trials report up to 20% total body-weight reduction in some participants.
Emerging Dual Agonists
• Several drugs are in late-stage clinical trials, aiming to optimize dosing and reduce side effects.
• Expected FDA approvals could expand treatment options within the next 1–2 years.
Talk to Your Healthcare Provider
Assess Other Factors
Combine Medication with Lifestyle
Monitor Progress
Always report serious or persistent symptoms—like severe abdominal pain, rapid heartbeat, or allergic reactions—to your doctor immediately.
If you experience any of the following, speak to a healthcare professional without delay:
Before your appointment, use Ubie's AI-powered symptom checker to document your symptoms and get personalized health insights that can help you have a more productive conversation with your doctor.
Weight-loss plateaus can be frustrating, but understanding the hormonal drivers—especially the role of GIP peptides—opens new doors for effective treatment. Medically approved GIP/GLP-1 dual agonists like tirzepatide have demonstrated impressive results in clinical trials. Pairing these medications with personalized lifestyle changes, regular monitoring, and professional guidance offers the best chance to break through a stall safely and sustainably.
Remember: always discuss any new treatment or concerning symptoms with your doctor. Serious or life-threatening issues require immediate medical attention. Success in weight management often comes from combining science-based therapies with consistent, healthy habits—and the support of medical professionals.
(References)
* Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
* Nauck MA, et al. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) in obesity and weight loss: a narrative review. Obes Rev. 2024 Jan;25(1):e13636. doi: 10.1111/obr.13636. Epub 2023 Nov 2. PMID: 37916964.
* Müller TD, et al. GIP receptor agonists for the treatment of obesity and related metabolic diseases. Nat Rev Endocrinol. 2022 Sep;18(9):515-528. doi: 10.1038/s41574-022-00681-3. Epub 2022 May 11. PMID: 35545622.
* Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Gasbjerg LS, et al. GIP and its role in obesity, glucose homeostasis, and nutrient sensing. Trends Endocrinol Metab. 2020 Aug;31(8):561-574. doi: 10.1016/j.tem.2020.04.010. Epub 2020 May 29. PMID: 32475659.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.